Spectrum Pharmacy Products, a top manufacturer and distributor of pharmaceutical chemicals and supplies, is partnering with the Independent Pharmacy Alliance (IPA), a retail pharmacy and trade group that represents thousands of pharmacies in the Northeastern U.S., PR Newswire reported. Read More »
To better assess patients’ oral and pharyngeal functioning for the purpose of easing swallowing disorders, the U.S. Food and Drug Administration recently approved Bracco Diagnostics Inc.’s Varibar Nectar (barium sulfate) Oral Suspension. Read More »
Animal health specialist firm Zoetis of Parsippany, New Jersey recently completed an approximately $85 million acquisition of Irish biologic therapeutics business Nexvet Biopharma PLC, with the deal expected to boost the company’s market share. Read More »
Cumberland Pharmaceuticals, specializing in therapies for underserved populations, has begun shipping its Totect brand of dexrazoxane, for alleviating certain side effects of chemotherapy during cancer treatment, to U.S. wholesalers. Read More »
Following successful clinical results, Vertex Pharmaceuticals Inc. recently gained approval from the U.S. Food and Drug Administration (FDA) to treat more than 600 cystic fibrosis (CF) patients with its proprietary Kalydeco (ivacaftor) product. Read More »
Spectrum Pharmaceuticals Inc., a biotechnology company focusing on hematology and oncology, recently completed enrollment for its Rolontis Phase 3 Advance pivotal study. Read More »
Celgene Corp. and Agios Pharmaceuticals Inc. recently received U.S. Food and Drug Administration approval for IDHIFA as a treatment for adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with an isocitrate dehydrogenase-2 (IDH2) mutation. Read More »
Neovacs, a company focusing on immunotherapies that treat autoimmune diseases, recently announced its Investigation New Drug application for IFNalpha Kinoid was cleared by the U.S. Food and Drug Administration. Read More »
Pharmacy Times, the leading media resource for pharmacists and the pharmacy industry, ranked highest in ad visibility and highest in readership in the 2017 Kantar Media Pharmacy Readership study. Read More »
Amgen and Allergan submitted a Biologics License Application for ABP 980, a biosimilar candidate to Herceptin, to the U.S. Food and Drug Administration. Read More »
Novartis, an immunology and dermatology company, recently reported positive five-year efficacy and safety results for Cosentyx after completing a Phase III long-term extension study in patients with moderate-to-severe plaque psoriasis. Read More »
Thermo Fisher Scientific recently received U.S. Food and Drug Administation 510(k) clearance for the company’s new immunoassay for the specific detection of buprenorphine and its three major metabolites. Read More »
Cidara Therapeutics Inc., a biotechnology company with a focus on developing anti-infective immunotherapies, recently published data from a study analyzing its next-generation echinocandin agent as a comparison to the treatment for intra-abdominal candidiasis. Read More »
Biothera Pharmaceuticals Inc. recently announced that the patient dosing has begun in a Phase 1b/2 clinical study at the Big Ten Cancer Research Consortium to evaluate Biothera’s Imprime PGG in combination with the Merck anti-PD-1 therapy, Keytruda (pembrolizumab), in second-line non-small cell lung cancer. Read More »
Gilead Sciences Inc.'s updated labeling for Epclusa has been approved by the U.S. Food and Drug Administration. Read More »
Making progress in the fight against opioid abuse, California-based Opiant Pharmaceuticals Inc. recently obtained a U.S. patent for its 2mg formula of Narcan Nasal Spray and product inclusion in U.S. Food and Drug Administration’s listings. Read More »
Upping its game against certain candida, tuberculosis and gonorrhea strains, the U.S. Centers for Disease Control and Prevention recently allotted more than $200 million to help jurisdictions curtail both emerging and re-emerging infectious diseases. Read More »
An innovative new asthma treatment from Teva Pharmaceutical Industries Ltd. recently gained U.S. Food and Drug Administration approval, permitting the breath-activated inhaler to enter the market as a prophylactic maintenance medication. Read More »
Resolving a contractual dispute dating to 2010 regarding three-way collaboration on Opana ER tablets — between Impax Laboratories, Endo International plc and Penwest Pharmaceuticals — Impax recently revealed a mutual settlement agreement from its Hayward, California hub. Read More »
The first eight-week medication cycle for chronic hepatitis C virus (HCV) recently earned approval from the U.S. Food and Drug Administration (FDA) in the form of Mavyret (glecaprevir and pibrentasvir), shortening treatment duration by one-third. Read More »
Alerts Sign-up
